NCT02276300View on ClinicalTrials.gov

HER2-Peptide Vaccination of Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 18, 2017

Study Completion Date

July 13, 2018

Conditions
Gastric CancerBreast Cancer
Interventions
DRUG

Cyclophosphamide

Treatment of mild Endoxan application three days before Her2 vaccination

DRUG

Sargramostim

Sargramostim is part of Her2 vaccination

DRUG

HER2-Peptid-Vakzine

Her2 vaccination is supplemented by Sargramostim and Aldara Creme application

DRUG

Imiquimod

Imiquimod is part of Her2 vaccination

Trial Locations (1)

81675

III.Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der TUM, Munich

All Listed Sponsors
lead

Technical University of Munich

OTHER

NCT02276300 - HER2-Peptide Vaccination of Patients With Solid Tumors | Biotech Hunter | Biotech Hunter